A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

  • David G. Sweet, Henry L. Halliday
  • Drug Safety, January 2000, Springer Science + Business Media
  • DOI: 10.2165/00002018-200022050-00006

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.2165/00002018-200022050-00006

The following have contributed to this page: Professor Henry L Halliday